Selective removal of age-modified cells for treatment of atherosclerosis
AssigneeSiwa Corporation
InventorLewis Gruber
Life of this patent
Estimating the term…
Abstract
A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.
Claims20
An anti-AGE humanized monoclonal antibody for the treatment of atherosclerosis, wherein the anti-AGE humanized monoclonal antibody is conjugated to at least one agent selected from the group consisting of a toxin or a cytotoxic agent, magnetic nanoparticles, and magnetic spin-vortex discs.
A pharmaceutical composition for the treatment of atherosclerosis comprising:
- an effective amount of an anti-AGE humanized monoclonal antibody, and
- at least one pharmaceutically acceptable excipient,
- wherein the anti-AGE humanized monoclonal antibody is conjugated to at least one agent selected from the group consisting of a toxin or a cytotoxic agent, magnetic nanoparticles, and magnetic spin-vortex discs.
A method of treating atherosclerosis comprising:
- removing AGE-modified cells from a patient, wherein the AGE-modified cells are removed by binding with an anti-AGE monoclonal antibody.
Dependencies are inferred from the claim text.